Save time and get answers to complex questions with AI chat
Allergan's patent for latisse expired?Somatuline depot patent expiry date?Zemdri plazomicin nce gain exclusivity 2028 patent 2031?When is xarelto's patent set to expire roughly?Bivalirudin manufacturer?
See the DrugPatentWatch profile for Myrbetriq
Myrbetriq (mirabegron) is a medication for overactive bladder. Its mechanism of action is based on blocking beta-3 adrenergic receptors in the bladder. By activating beta-3 signaling to relax the detrusor muscle, mirabegron helps increase bladder capacity and reduce urgency and frequency of urination [1].
Overactive bladder symptoms often relate to involuntary detrusor contractions. Mirabegron works by relaxing the detrusor (bladder) muscle through beta-3 adrenergic receptor activity, which helps the bladder store more urine before the urge to urinate occurs [1].
No. Antimuscarinics (another common overactive bladder drug class) work by blocking muscarinic receptors. Mirabegron instead targets beta-3 adrenergic receptors, so its approach is different at the receptor level [1].
Because the drug increases functional bladder capacity and reduces urgency/frequency, mirabegron is used for overactive bladder, including symptoms like urgency, frequent urination, and urge incontinence [1].
Other Questions About Myrbetriq :